Prescriptions are skyrocketing: heres why The surge in GLP-1 prescriptions reflects both expanding FDA approvals and growing public awareness
Here is a quick snapshot of where each medication stands: Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss): Greater average weight loss in trials, dual receptor mechanism, no FDA-approved cardiovascular outcomes indication as of 2026 Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss): Slightly lower average weight loss, single receptor mechanism, FDA-approved for reducing major cardiovascular events in patients with established heart disease Administration: Both are once-weekly injections
Semaglutide helps control appetite, but lifestyle changes are still necessary for long-term success in losing weight and keeping it off
Get the blood test done early
10.3390/nu8010053 [DOI] [PMC free article] [PubMed] [Google Scholar] 69.Liu J, Sun Y, Zhang H, Ji D, Wu F, Tian H, et al
Cellular Recovery & Repair Improved tissue turnover supports recovery from injury, training, and overall longevity-focused goals
